A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT07220616 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: DS3790a
DRUG: Combination drug
DRUG: Combination drug

Sponsor

Daiichi Sankyo